Local treatment for advanced lung cancer that hasn’t worsened
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at whether using focused treatments (like surgery or radiation to lung cancer spots) can help people with advanced non-small cell lung cancer whose disease has not progressed after first-line treatment. It’s meant for people who have limited metastatic spots and can safely undergo the local treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 or older and can likely live at least 12 weeks
- You have stage IV (metastatic) non-small cell lung cancer confirmed by tests
- Your tumor has been tested for EGFR, ALK, and ROS1 gene changes
- After first treatment (chemo, targeted therapy, or immunotherapy), your cancer response was complete, partial, or stable (not progressing)
- You have 5 or fewer metastatic spots that doctors can count
- Your body is strong enough for treatment (performance status 0–2) and your blood, liver, kidney, and clotting labs are within allowed limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
This trial tests a personalized immune cell therapy for advanced or relapsed lung cancer. Doctors take your blood, create special T cells that target unique proteins on your cancer, and give them back to you to try to fight the tumor.
This study tests a new cell therapy (BST08) for people with advanced non-small cell lung cancer that has not improved after at least two prior treatments. The treatment is made from a sample of your own tumor, so it may be a personalized option for you.
This trial tests if focusing treatment on a few new or growing lung tumors can help people with lung cancer who are already on systemic therapy. You may qualify if you have stable disease overall but a small number of new spots that can be safely treated with radiation or other local procedures.
This trial compares continuing drug therapy alone versus adding local treatments (surgery or radiation) for people with stage IV lung cancer that has responded to initial treatment but still has a few remaining spots (oligometastatic). The goal is to see if targeting those spots with local therapy helps control the cancer longer.
Hear when a new Lung Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.